Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients - Wikidata - wikimedia - TriplyDB

Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients

Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients

http://www.wikidata.org/entity/Q42656427

about

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients Regulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservation Issues in solid-organ transplantation in children: translational research from bench to bedside.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Bortezomib use in a pediatric cardiac transplant center.Pediatric heart transplantation-indications and outcomes in the current era.Coincidence of cellular and antibody mediated rejection in heart transplant recipients - preliminary report.Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States Tolerogenic therapies in transplantation.Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig.Increased levels of anti-non-Gal IgG following pig-to-baboon bone marrow transplantation correlate with failure of engraftment Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.New immunosuppressive agents in pediatric transplantation.Significance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes.On the role of HLA antibodies in hematopoietic stem cell transplantation.Human leukocyte antigens and alloimmunization in heart transplantation: an open debate.Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management.Emerging science in paediatric heart transplantation: donor allocation, biomarkers, and the quest for evidence-based medicine.Novel therapeutic and diagnostic management of heart transplant patients.The importance of non-HLA antibodies in transplantation.Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients.Changes in the methodology of pre-heart transplant human leukocyte antibody assessment: an analysis of the United Network for Organ Sharing database.Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information.Results of heart transplantation following failed staged palliation of hypoplastic left heart syndrome and related single ventricle anomalies.Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience.Interferon Gamma and Contact-dependent Cytotoxicity Are Each Rate Limiting for Natural Killer Cell-Mediated Antibody-dependent Chronic Rejection.Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model.Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.Role of C1q complement fixing antibody assay in therapeutic plasma exchange management of pediatric cardiac antibody mediated rejection.Current Expectations for Cardiac Transplantation in Patients With Congenital Heart Disease.

P2860

Q26774993-722CC47C-F215-43AA-8E99-7FA36AD52DFC Q27000202-F19315E5-9C4E-4C7C-AF28-A46874F608F2 Q27023312-717CEA8C-B9F4-4342-B04D-AAD81FFF7FFC Q30276550-722B4B6F-7A50-4303-82EC-66F020B6848C Q33415926-975CE5D3-B526-46B7-96DE-1F651AD04922 Q34048053-83F585EE-9F91-477D-BCB8-14A42F26322F Q34821994-C51ABC6C-0357-4C94-929E-F50232C875F5 Q35957567-6839CA4A-2AEC-4A62-B568-89459BCCEF4F Q36102133-52E20D90-D6B7-4FAD-AB07-6480C5D3BB04 Q37231896-4CA68A1D-5922-4DFA-BF7D-74EA28D27666 Q37358501-06F44331-9500-48A0-B821-B7DBF6A8ADD0 Q37361071-112C2034-1F74-438D-B2CB-A5C5A3A081DB Q37446883-9794197D-8C84-485F-A570-4483F7343A92 Q37609092-F5211D94-74DE-4D44-8B11-4EA0ED4F8BC1 Q38065269-258FDF38-C825-447A-B708-0AE495309CC4 Q38246225-581C439D-3092-49BB-A9C2-705D7002DC0E Q38392458-655B0025-3818-4136-BDC6-BE401E1F2331 Q38588170-72F09129-2054-44F8-B19A-6AD9E9DC3B50 Q38614686-B953C8C5-D5D4-428E-BDCA-DD8D30699697 Q38877375-04433E7F-F22F-487B-A34B-EE089BD7096E Q38945149-76EE6AF6-1A21-45F8-B810-75609D95922E Q40739859-0F1FE84B-4042-46FF-B163-AFA7BD97FE0F Q40990548-3F990B7E-90AA-4B4E-823D-877EA54B6629 Q41559290-91925EE5-5F09-4EB2-83BD-62920A7CA80D Q42280145-C4043D3A-61A0-48C5-9B4D-F0BB1B28231C Q42721586-C3B01EF8-1955-408F-9CED-86AEF9D2951F Q46207877-F92533A0-D37D-4627-A6C3-86138D15DC63 Q46402292-CFAA51CD-D8F1-43B9-98D3-A85F6D26835B Q48135398-858DBC53-0EDC-4B2E-BAC6-3DC4A3F7E37F Q51102400-4696991D-58A1-499E-BEC3-7D34E903D0DA

P2860

Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients

http://www.wikidata.org/entity/Q42656427

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Rapid reduction in donor-speci ...... tric heart transplant patients

@en

Rapid reduction in donor-speci ...... tric heart transplant patients

@nl

type

label

Rapid reduction in donor-speci ...... tric heart transplant patients

@en

Rapid reduction in donor-speci ...... tric heart transplant patients

@nl

prefLabel

Rapid reduction in donor-speci ...... tric heart transplant patients

@en

Rapid reduction in donor-speci ...... tric heart transplant patients

@nl

P1433

Q42656427-DC9CD030-7510-4D87-8E44-245FAF2B56CC

P1476

Q42656427-76917C67-89BD-45D6-ACF9-61126F81C438

P2093

Q42656427-0840FF50-451F-453F-8F3A-9F72AB5E2458

Q42656427-198A379C-0648-4CD5-BD84-541A5324F029

Q42656427-1A28FE7A-9B9D-409E-B8FB-CE88F26D27A1

Q42656427-3AA2F8DA-95D2-4465-954E-F490DBB7B906

Q42656427-41A9A8B1-A5A7-4404-842B-8064ED097DC9

Q42656427-4518967F-EC0D-465B-98E0-2747AE49392A

Q42656427-56ED7E60-1600-473F-AB04-65BB59F51A92

Q42656427-5AAA821E-D836-4DE8-98F1-AFCF520A7BDE

Q42656427-A589A682-CC99-4544-86DE-F4DB72AE1299

Q42656427-F0971CF3-C1C8-4DD6-9E31-02995FCAABC7

P2860

Q42656427-1F8A6CBA-83DE-4A7A-83BF-1EC81806BB7E

Q42656427-22F1AA83-6B48-48D7-B118-D65DFA1AB700

Q42656427-2CD7406B-B224-45C7-A0D1-27A3C46B5AFE

Q42656427-3547C2D2-4673-4BDA-A0E2-FE090D911495

Q42656427-47E9B762-896A-41B9-8A27-4D409832C73A

Q42656427-54DA2B2B-D0DF-49AB-9129-07BDEF84A007

Q42656427-568FC5DA-C11F-4666-BC6A-DCF65C60CB79

Q42656427-5C835215-2634-47B6-A998-89551E39AD9D

Q42656427-5E812217-67FA-4DDB-A253-4380E4EC70FE

Q42656427-7A6EFAB8-E742-48A1-BCB2-EB38FF85F37B

P304

Q42656427-FE2A5919-6DC3-4E5C-8292-73A916454EA0

P31

Q42656427-E997077F-CB0A-4AD0-95C9-DC51DEB8A55D

P356

Q42656427-2C11FCAE-DFA7-4F91-A226-931134F4F105

P433

Q42656427-BC74A021-47FF-4D30-9776-6320A17216C4

P478

Q42656427-AAF4DC42-03C6-4940-84D3-B45A302A36D3

P577

Q42656427-F3F18FB0-0A66-4AB5-B955-4840F454B4F3

P698

Q42656427-D4A4D4E5-89D6-41C2-806C-C9935E4524C9

P921

Q42656427-4C8FEF86-D846-4250-AA88-DE4800DB7D34

P932

Q42656427-76B23322-842D-4684-8550-31E7F2F839C4

P356

TP.0B013E31823F7EEA

P1433

Transplantation

P1476

Rapid reduction in donor-speci ...... tric heart transplant patients

@en

P2093

E Steve Woodle

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Frazier

http://www.w3.org/2001/XMLSchema#string

Emily L Howard

http://www.w3.org/2001/XMLSchema#string

Kenneth R Knecht

http://www.w3.org/2001/XMLSchema#string

R Neal Smith

http://www.w3.org/2001/XMLSchema#string

Robert D B Jaquiss

http://www.w3.org/2001/XMLSchema#string

Robert L Saylors

http://www.w3.org/2001/XMLSchema#string

Sherry E Pye

http://www.w3.org/2001/XMLSchema#string

Terry O Harville

http://www.w3.org/2001/XMLSchema#string

William Robert Morrow

http://www.w3.org/2001/XMLSchema#string

P2860

Management of allosensitized cardiac transplant candidates

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection.

Preformed anti-human leukocyte antigen antibodies jeopardize cardiac transplantation in patients with a left ventricular assist device.

Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection.

De novo production of antibodies after heart or lung transplantation should be regarded as an early warning system.

Pediatric cardiac transplantation in children with high panel reactive antibody.

Acute antibody-mediated rejection of cardiac transplants.

Role of alloantibodies in the pathogenesis of graft arteriosclerosis in cardiac transplantation.

P304

319-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/TP.0B013E31823F7EEA

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22179403

http://www.w3.org/2001/XMLSchema#string

P921

P932

3730122

http://www.w3.org/2001/XMLSchema#string